Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, characterized by accumulation of fat in the liver cells in people who drink little to no alcohol. Its prevalence is escalating, in tandem with the global rise in obesity and type 2 diabetes, making it a significant concern for healthcare providers.
Prevention strategies primarily revolve around lifestyle modifications. Encouraging patients to adopt a balanced diet, increase physical activity, and achieve a healthy body weight can significantly reduce the risk of developing NAFLD. Regular screening for metabolic risk factors such as hyperlipidemia, hypertension, and diabetes is also crucial in early detection and prevention.
Diagnosis of NAFLD involves a combination of medical history, physical examination, and laboratory tests. Imaging techniques such as ultrasound, CT, and MRI can be used to detect fatty liver, while liver biopsy remains the gold standard for diagnosing and staging NAFLD. Non-invasive tests, including transient elastography and serum biomarkers, are emerging as promising tools for diagnosing and monitoring disease progression.
Currently, there is no approved pharmacological therapy for NAFLD. The mainstay of treatment is lifestyle modification aimed at weight loss. In patients with NASH, vitamin E and pioglitazone have shown benefits. For advanced disease, liver transplantation may be considered. Ongoing research is focused on developing targeted therapies to address the underlying pathophysiology of NAFLD.
NAFLD is a growing health concern that necessitates proactive prevention, early detection, and effective management strategies. Healthcare professionals play a pivotal role in this endeavor. Keeping abreast of the latest research and advances in the field will ensure optimal patient care and outcomes in managing this complex disease.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation